Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Abstract Introduction Patients with pretreated relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and limited treatment options, underscoring the need for safe treatments with durable efficacy. Methods This Phase 2 study evaluated magrolimab (Magro) plus daratumumab (Dara) or pomalido...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Barry Paul, Jiri Minarik, Francesca Cottini, Cristina Gasparetto, Jack Khouri, Mitul Gandhi, Jens Hillengass, Moshe Levy, Michaela Liedtke, Sudhir Manda, Irwindeep Sandhu, Douglas Sborov, Ivan Spicka, Saad Usmani, Mei Dong, Lin Gu, Carmen Leung, Parul Doshi, Christine Chen, Ludek Pour
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2025-06-01
Colecção:	eJHaem
Assuntos:	carfilzomib daratumumab dexamethasone magrolimab pomalidomide relapsed/refractory multiple myeloma
Acesso em linha:	https://doi.org/10.1002/jha2.70072
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!